Secondary Logo

Institutional members access full text with Ovid®

Ganglioglioma in a Survivor of Infantile Glioblastoma

Scheuermann, Amanda, DO*; Belongia, Meghan, APNP*,†; Lawlor, Michael W., MD, PhD; Suchi, Mariko, MD, PhD; Kaufman, Bruce, MD§; Vasudevaraja, Varshini, MSc; Serrano, Jonathan, BSc; Snuderl, Matija, MD; Knipstein, Jeffrey, MD*,†

Journal of Pediatric Hematology/Oncology: January 22, 2019 - Volume Publish Ahead of Print - Issue - p
doi: 10.1097/MPH.0000000000001417
Clinical and Laboratory Observations: PDF Only

Congenital tumors account for 2% to 4% of all pediatric central nervous system tumors. Glioblastoma multiforme (GBM) represents a small subset of these tumors. Despite harboring histologic features similar to older patients, infants with GBM exhibit improved survival and respond more favorably to surgery and chemotherapy. To highlight this tumor’s unique behavior, we report the case of a survivor of infantile GBM who developed a recurrent tumor in the surgical bed 6 months after diagnosis. The tumor was ultimately resected and was a ganglioglioma. This case shows both a favorable clinical outcome to an infantile GBM and this tumor’s natural history.

Departments of *Pediatrics

Pathology and Laboratory Medicine


Division of Pediatric Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI

Department of Pathology, New York University, New York, NY

M.W.L. is a member of advisory boards and receives research support from Audentes Therapeutics, Solid Biosciences, and Ichorion Therapeutics.

M.W.L. is a consultant for Wave Life Sciences, Valerion Therapeutics, and Dynacure. The remaining authors declare no conflict of interest.

Reprints: Amanda Scheuermann, DO, 8701 W Watertown Plank Road, Milwaukee, WI 53226 (e-mail:

Received May 17, 2018

Accepted December 1, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.